These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 29795465)
1. Paternal cholestasis exacerbates obesity-associated hypertension in male offspring but is prevented by paternal ursodeoxycholic acid treatment. Pataia V; Papacleovoulou G; Nikolova V; Samuelsson AM; Chambers S; Jansen E; Taylor PD; Poston L; Williamson C Int J Obes (Lond); 2019 Feb; 43(2):319-330. PubMed ID: 29795465 [TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2 Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946 [TBL] [Abstract][Full Text] [Related]
3. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Purucker E; Marschall HU; Winograd R; Matern S Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121 [TBL] [Abstract][Full Text] [Related]
4. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases]. Arrese M; Accatino L Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619 [TBL] [Abstract][Full Text] [Related]
5. Programming of obesity and comorbidities in the progeny: lessons from a model of diet-induced obese parents. Ornellas F; Souza-Mello V; Mandarim-de-Lacerda CA; Aguila MB PLoS One; 2015; 10(4):e0124737. PubMed ID: 25880318 [TBL] [Abstract][Full Text] [Related]
6. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Beuers U Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551 [TBL] [Abstract][Full Text] [Related]
8. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA). Chazouillères O; Marteau P; Haniche M; Jian R; Poupon R Dig Dis Sci; 1996 Dec; 41(12):2417-22. PubMed ID: 9011452 [TBL] [Abstract][Full Text] [Related]
9. Therapy with ursodeoxycholic acid in cholestatic liver disease. Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564 [TBL] [Abstract][Full Text] [Related]
11. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. Stiehl A; Rudolph G; Sauer P; Theilmann L J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of cholestatic liver diseases]. Gatzen M; Pausch J Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790 [TBL] [Abstract][Full Text] [Related]
13. Lack of benefit of ursodeoxycholic acid in drug-induced cholestasis in the rat. Hillstrom J; Duane WC; Eckfeldt JH; Furne J; Levitt MD Proc Soc Exp Biol Med; 1992 May; 200(1):122-6. PubMed ID: 1570353 [TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Poo JL; Feldmann G; Erlinger S; Braillon A; Gaudin C; Dumont M; Lebrec D Gastroenterology; 1992 May; 102(5):1752-9. PubMed ID: 1568585 [TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis. Scher H; Bishop WP; McCray PB Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240 [TBL] [Abstract][Full Text] [Related]
16. Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. Di Guida F; Pirozzi C; Magliocca S; Santoro A; Lama A; Russo R; Nieddu M; Burrai L; Boatto G; Mollica MP; Sodano F; Lazzarato L; Chegaev K; Meli R; Raso GM; Rimoli MG Mol Pharm; 2018 Jan; 15(1):21-30. PubMed ID: 29140706 [TBL] [Abstract][Full Text] [Related]
17. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414 [TBL] [Abstract][Full Text] [Related]
18. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate. Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001 [TBL] [Abstract][Full Text] [Related]
19. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies. Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895 [TBL] [Abstract][Full Text] [Related]
20. Stress-induced body weight loss and improvements in cardiometabolic risk factors do not translate to improved myocardial ischemic tolerance in western diet-fed mice. Hatton-Jones K; Cox AJ; Peart JN; Headrick JP; du Toit EF Physiol Rep; 2022 Jan; 10(2):e15170. PubMed ID: 35076176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]